BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cephalon, Inc. (CEPH)Takeover Offer for Arana Therapeutics Declared Unconditional


5/21/2009 1:57:16 PM

Thursday 21 April 2009 - The Directors of Arana Therapeutics Limited (‘Arana’) provide this update to inform Arana shareholders that the takeover offer from Cephalon, Inc (the ‘Cephalon Offer’) has now been declared unconditional. This means that upon Arana shareholders accepting the Cephalon Offer, they will be sent their cash consideration within five business days of the receipt of their valid acceptance by Cephalon.

Cephalon has also declared its offer final. This means that Cephalon can not by law increase the Offer from $1.40, except for the increase to $1.45 per Arana share if Cephalon obtains a relevant interest in 90% of Arana shares during the Offer period.

As previously communicated, the Cephalon Offer is adjusted for the five cent per share special dividend which has already been paid. This means that you will receive $1.35 per share in cash after accepting the offer unless Cephalon obtains a 90% relevant interest in which case you will receive $1.40 per share in cash.

The Cephalon Offer is scheduled to close, unless extended, on 1 June 2009.

Cephalon now has an interest in 53.44% of Arana. If Cephalon does not gain 90% acceptance, it will still have effective control of Arana. Arana shareholders who do not accept the Cephalon Offer in accordance with the terms of the Offer will remain shareholders in Arana. This may have a number of implications for remaining Arana shareholders. These implications are discussed in detail on page 27 of the Arana Target’s Statement dated 24 March 2009.

The Directors of Arana continue to recommend that, in the absence of a superior proposal, you ACCEPT the Cephalon Offer. Importantly, the Cephalon Offer is the only offer available to Arana shareholders and the Directors have now accepted the Cephalon offer in respect of all the shares in Arana that they own or control.

If you have any further questions on this announcement please contact the Arana shareholder information line on 1300 206 331 or +61 2 9237 2800 if calling from outside Australia.

About Arana Therapeutics:

Arana Therapeutics (ASX: AAH) is a biopharmaceutical company focused on developing next generation antibody based drugs that will improve the lives of patients with inflammatory diseases and cancer.

Arana Therapeutics’ innovative engineering technologies provide the basis for developing its next generation antibody candidates. Arana Therapeutics has the financial strength and management expertise to develop its product pipeline.

Arana has a significant track record of commercialising its technologies and has collaborations with GlaxoSmithKline (GSK), CSL, Kyowa Hakko Kirin (KHK), and licensing arrangements with Centocor (J&J) and Abbott Laboratories.

For further information: www.arana.com.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->